6-month, Open-label, Randomized, Multicenter, Prospective, Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program.

Trial Profile

6-month, Open-label, Randomized, Multicenter, Prospective, Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program.

Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs Basiliximab (Primary) ; Everolimus (Primary) ; Ciclosporin; Mycophenolate sodium
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms SENATOR
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 21 Mar 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 21 Apr 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2008-005109-20).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top